Trevi Therapeutics, Inc. (TRVI) Ownership
TRVI ownership summary
as of October 18, 2026- Institutions
- 109.1% of shares outstanding
- Insiders
- 0.63% of shares outstanding
- Shares outstanding
- 142.5M
- Float
- 118.3M shares available to trade
- Short interest
- 11.41% 14.6M shares short
- Days to cover
- 9.10 short interest up 21.3% vs prior month
- Institutions 109.10%
- Insiders 0.63%
TRVI top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | NEA Management Company, LLC | 9.28% | 13.2M | $157.1M | — | June 30, 2026 |
| 2 | FMR Inc | 8.82% | 12.6M | $149.2M | +4.5M (+56.3%) | June 30, 2026 |
| 3 | BlackRock Inc | 7.83% | 11.2M | $132.5M | +914,840 (+8.9%) | June 30, 2026 |
| 4 | Frazier Life Sciences Management, L.P. | 6.98% | 9.9M | $118.1M | −100 (−0.0%) | June 30, 2026 |
| 5 | Wellington Management Company LLP | 3.99% | 5.7M | $67.5M | +495,504 (+9.5%) | June 30, 2026 |
| 6 | Vanguard Capital Management, LLC | 3.88% | 5.5M | $65.7M | +552,108 (+11.1%) | June 30, 2026 |
| 7 | Vivo Capital, LLC | 3.58% | 5.1M | $60.5M | — | June 30, 2026 |
| 8 | Woodline Partners LP | 2.86% | 4.1M | $48.5M | +3.1M (+307.8%) | June 30, 2026 |
| 9 | Vestal Point Capital LP | 2.18% | 3.1M | $36.8M | +933,496 (+43.1%) | June 30, 2026 |
| 10 | MPM Oncology Impact Management LP | 2.16% | 3.1M | $36.5M | −224,853 (−6.8%) | June 30, 2026 |
| 11 | Frontier Capital Management CO Inc | 2.16% | 3.1M | $36.5M | +1.1M (+54.0%) | June 30, 2026 |
| 12 | Assenagon Asset Management SA | 2.14% | 3.1M | $36.2M | +3.1M (0.0%) | June 30, 2026 |
| 13 | State Street Corp | 2.12% | 3.0M | $36.0M | +362,002 (+13.6%) | June 30, 2026 |
| 14 | Geode Capital Management, LLC | 2.06% | 2.9M | $34.8M | +149,837 (+5.4%) | June 30, 2026 |
| 15 | Marshall Wace Asset Management Ltd | 1.88% | 2.7M | $31.8M | −1.3M (−32.6%) | June 30, 2026 |
| 16 | Eventide Asset Management, LLC | 1.87% | 2.7M | $31.6M | +37,694 (+1.4%) | June 30, 2026 |
| 17 | Rubric Capital Management LP | 1.76% | 2.5M | $29.8M | −1.2M (−32.5%) | June 30, 2026 |
| 18 | AllianceBernstein L.P. | 1.65% | 2.4M | $28.0M | −490,019 (−17.2%) | June 30, 2026 |
| 19 | Artia Global Partners LP | 1.55% | 2.2M | $26.3M | +197,250 (+9.8%) | June 30, 2026 |
| 20 | First Light Asset Management, LLC | 1.47% | 2.1M | $24.9M | +2.1M (0.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 17.5M shares and 5 cut 3.2M.
TRVI top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.85% | 4.1M | $48.2M | −6,590 (−0.2%) | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 1.98% | 2.8M | $33.5M | −32,512 (−1.1%) | September 30, 2026 |
| 3 | Eventide Healthcare & Life Sciences I | 1.87% | 2.7M | $31.6M | +37,694 (+1.4%) | June 30, 2026 |
| 4 | Fidelity Select Biotechnology | 1.67% | 2.4M | $28.2M | — | August 31, 2026 |
| 5 | Fidelity Small Cap Growth | 1.37% | 2.0M | $23.2M | — | July 31, 2026 |
| 6 | Pictet-Biotech P USD | 0.93% | 1.3M | $15.8M | +217,398 (+19.6%) | June 30, 2026 |
| 7 | Fidelity Small Cap Index | 0.82% | 1.2M | $13.9M | +10,108 (+0.9%) | July 31, 2026 |
| 8 | MEDICAL BioHealth EUR Acc | 0.77% | 1.1M | $13.0M | +232 (+0.0%) | August 31, 2026 |
| 9 | Fidelity Growth Company Fund | 0.73% | 1.0M | $12.3M | — | August 31, 2026 |
| 10 | iShares Russell 2000 Growth ETF | 0.72% | 1.0M | $12.2M | −1,298 (−0.1%) | September 30, 2026 |
| 11 | AB Small Cap Growth A | 0.72% | 1.0M | $12.2M | −8,380 (−0.8%) | August 31, 2026 |
| 12 | Fidelity Small Cap Growth K6 | 0.69% | 990K | $11.8M | — | July 31, 2026 |
| 13 | HBM Healthcare Investments AG Ord | 0.69% | 987K | $11.7M | +100,000 (+11.3%) | June 30, 2026 |
| 14 | Fidelity Select Health Care | 0.67% | 950K | $11.3M | — | August 31, 2026 |
| 15 | Principal SmallCap Growth I Instl | 0.55% | 780K | $9.3M | +3,895 (+0.5%) | August 31, 2026 |
| 16 | Candriam Eqs L Biotech C USD Cap | 0.54% | 774K | $9.2M | +653,976 (+546.6%) | March 31, 2026 |
| 17 | Fidelity VIP Mid Cap Initial | 0.54% | 765K | $9.1M | — | August 31, 2026 |
| 18 | iShares Biotechnology ETF | 0.53% | 752K | $8.9M | −5,696 (−0.8%) | September 30, 2026 |
| 19 | Schwab US Small-Cap ETF™ | 0.44% | 631K | $7.5M | +423 (+0.1%) | September 30, 2026 |
| 20 | State Street® SPDR® S&P® PhrmctlsETF | 0.44% | 626K | $7.4M | −7,778 (−1.2%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
TRVI insider transactions
latest 17| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-21 | Jennifer L Good | Sell | $6.58 | 5,263 | $34,631 |
| 2025-03-10 | Farrell Simon | Sell | $6.75 | 81,313 | $548,863 |
| 2024-09-09 | Jennifer L Good | Sell | $3.04 | 1,840 | $5,594 |
| 2024-09-06 | Jennifer L Good | Sell | $3.03 | 4,219 | $12,784 |
| 2024-09-04 | Jennifer L Good | Sell | $3.02 | 10,981 | $33,163 |
| 2024-08-27 | David P Meeker | Sell | $2.93 | 4,555 | $13,346 |
| 2024-08-16 | Thomas Sciascia | Sell | $2.76 | 18,660 | $51,502 |
| 2024-08-14 | Thomas Sciascia | Sell | $2.75 | 100 | $275 |
| 2024-05-29 | Thomas Sciascia | Sell | $2.55 | 53,368 | $136,088 |
| 2024-05-22 | Lisa Delfini | Sell | $2.64 | 4,350 | $11,484 |
| 2024-05-20 | Jennifer L Good | Sell | $2.86 | 25,037 | $71,606 |
| 2024-05-10 | Jennifer L Good | Sell | $2.90 | 4,578 | $13,276 |
| 2023-10-11 | Lisa Delfini | Sell | $2.02 | 785 | $1,586 |
| 2023-09-11 | Lisa Delfini | Sell | $2.20 | 711 | $1,564 |
| 2023-08-11 | Lisa Delfini | Sell | $2.36 | 682 | $1,610 |
| 2023-07-11 | Lisa Delfini | Sell | $2.34 | 687 | $1,608 |
| 2023-06-12 | Lisa Delfini | Sell | $2.64 | 610 | $1,610 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
TRVI shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns TRVI
Institutional investors own 109.1% of Trevi Therapeutics's shares and insiders 0.63%. The largest holder is NEA Management Company, LLC with 9.28% of the shares (13.2M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 5 reduced their stake in the latest filings. Short interest is 11.41% of the float, or 9.10 days of average trading volume. The share count rose 1,059.2% since 2017.
Related: TRVI analyst forecast, TRVI key metrics. See the TRVI stock overview for the latest quote and news.
TRVI ownership FAQ
Who owns the most Trevi Therapeutics stock?
The largest shareholders of Trevi Therapeutics are NEA Management Company, LLC (9.28%), FMR Inc (8.82%), BlackRock Inc (7.83%), Frazier Life Sciences Management, L.P. (6.98%), Wellington Management Company LLP (3.99%).
What percentage of Trevi Therapeutics is owned by institutions?
Institutions hold 109.1% of Trevi Therapeutics's shares outstanding; insiders hold 0.63%.
Which funds own Trevi Therapeutics?
The largest fund holders of Trevi Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.85%), iShares Russell 2000 ETF (1.98%), Eventide Healthcare & Life Sciences I (1.87%), Fidelity Select Biotechnology (1.67%), Fidelity Small Cap Growth (1.37%).
What is Trevi Therapeutics's short interest?
14.6M shares of Trevi Therapeutics were sold short, 11.41% of the float; at the average daily volume it would take 9.10 days to cover.
Are insiders buying or selling Trevi Therapeutics?
Of the latest 17 reported insider transactions in Trevi Therapeutics (since June 12, 2023), 0 were purchases and 17 were sales.
How many shares of Trevi Therapeutics are outstanding?
Trevi Therapeutics has 142.5M shares outstanding, of which 118.3M are in the public float.